However, the diagnosis of APS in this patient suggested the autoimmune etiology of stroke, which would be consistent with a partial effectiveness of baricitinib in controlling STAT3-GOF-associated immune dysregulation, so that we will consider the reintroduction of a JAKi. The gene discussed is STAT3; the disease is stroke disorder.